Skip to NavigationSkip to content

Pharmafile - Research and Development

Giliad's Yesarta becomes second FDA-approved CAR T treatment and AstraZeneca admits efficacy data for an acquired cancer drug was fabricated. Check...
Research from scientists at the Wellcome Trust Sanger Institute has found that only between one and 10 genetic mutations are the driver behind many...
Celgene took a gamble when it spent $710 million up-front on an inflammatory disorder treatment, but it now looks likely to have been an expensive...
Eli Lilly has announced it is to partner up with CureVac to leverage its proprietary RNActive technology in order to develop and commercialise up...

Features

Peter Naredi, of ECCO, explores how a multi-dimensional approach is necessary to ensure that patients receive access to the most important medical...

Appointments

NHS Scotland has revealed the appointment of Professor David Crossman as its new Chief Scientist, after advertising externally to fill the...

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches